Dashboard
Manage Tickers

INBXInhibrx, Inc.

Nasdaq inhibrx.com


$ 34.05 $ -0.03 (-0.09 %)    

Friday, 26-Apr-2024 15:59:55 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 431.01 $ 6.55 (1.54 %)
DIA $ 382.27 $ 1.39 (0.36 %)
SPY $ 508.26 $ 4.77 (0.95 %)
TLT $ 88.26 $ 0.46 (0.52 %)
GLD $ 216.60 $ 0.70 (0.32 %)
$ 34.06
$ 34.08
$ 0.00 x 0
$ 0.00 x 0
$ 33.72 - $ 34.13
$ 14.31 - $ 39.79
200,367
na
1.61B
$ 1.93
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 02-28-2024 12-31-2023 10-K
2 11-09-2023 09-30-2023 10-Q
3 08-07-2023 06-30-2023 10-Q
4 05-08-2023 03-31-2023 10-Q
5 03-06-2023 12-31-2022 10-K
6 11-07-2022 09-30-2022 10-Q
7 08-08-2022 06-30-2022 10-Q
8 05-09-2022 03-31-2022 10-Q
9 02-28-2022 12-31-2021 10-K
10 11-09-2021 09-30-2021 10-Q
11 08-09-2021 06-30-2021 10-Q
12 05-13-2021 03-31-2021 10-Q
13 03-12-2021 12-31-2020 10-K
14 11-13-2020 09-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

inhibrx-q4-2023-gaap-eps-173-misses-104-estimate-sales-163m-beat-5000k-estimate
Inhibrx Q4 2023 GAAP EPS $(1.73) Misses $(...
02/28/2024 14:21:21

Inhibrx (NASDAQ:INBX) reported quarterly losses of $(1.73) per share which missed the analyst consensus estimate of $(1.04) by ...

french-drugmaker-sanofi-agrees-to-buy-inhibrxs-candidate-for-rare-genetic-indication-for-about-22b
French Drugmaker Sanofi Agrees To Buy Inhi...
01/23/2024 13:00:55

Sanofi's strategic acquisition of Inhibrx's INBRX-101, a alpha-1 antitrypsin therapy in a registrational trial. Learn a...

olympic-sponsor-sanofi-makes-major-play-in-rare-disease-arena-22-billion-acquisition-of-inhibrx-project
Olympic Sponsor Sanofi Makes Major Play In...
01/23/2024 12:46:00

Following the acquisition, New Inhibrx will continue to operate under the "Inhibrx" name, with Mark Lappe as Chairman a...

jmp-securities-downgrades-inhibrx-to-market-perform
JMP Securities Downgrades Inhibrx to Marke...
01/23/2024 09:34:28

JMP Securities analyst Reni Benjamin downgrades Inhibrx (NASDAQ:INBX) from Market Outperform to Market Perform.

Core News & Articles
Inhibrx Sells INBRX-101 To Sanofi For Up T...
01/23/2024 06:09:08

Inhibrx, Inc. shareholders will receive per share consideration of $30 per share in cash, a CVR equal to $5, plus 0.25 shares i...

jmp-securities-reiterates-market-outperform-on-inhibrx-maintains-27-price-target
JMP Securities Reiterates Market Outperfor...
11/20/2023 14:19:19

JMP Securities analyst Reni Benjamin reiterates Inhibrx (NASDAQ:INBX) with a Market Outperform and maintains $27 price target.

Core News & Articles
Watching Axos Financial; The Bear Cave New...
11/16/2023 15:34:17

https://thebearcave.substack.com/p/problems-at-axos-financial-ax?utm_campaign

inhibrx-q3-eps-110
Inhibrx Q3 EPS $(1.10)
11/09/2023 22:11:58

inhibrx-announces-preliminary-data-from-the-phase-1-trial-of-inbrx-109-for-the-treatment-of-ewing-sarcoma
Inhibrx Announces Preliminary Data From Th...
11/02/2023 13:20:33

Inhibrx, Inc. (NASDAQ:INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncolo...

inhibrx-announces-chiesi-farmaceutici-spa-declined-to-exercise-its-option-for-ex-north-america-rights-to-develop-and-commercialise-inbrx-101
Inhibrx Announces Chiesi Farmaceutici S.p....
09/19/2023 20:01:17

15m-bet-on-domo-check-out-these-3-stocks-insiders-are-buying
$1.5M Bet On Domo? Check Out These 3 Stock...
08/31/2023 11:58:22

Although U.S. stocks closed higher on Wednesday, there were a few notable insider trades.

why-nio-are-trading-lower-by-over-7-here-are-other-stocks-moving-in-tuesdays-mid-day-session
Why NIO Are Trading Lower By Over 7%? Here...
08/29/2023 16:51:54

Gainers Axcella Health Inc. (NASDAQ: AXLA) shares climbed 196% to $0.3335 after the company announced it was granted a pate...

pdd-holdings-up-fintech-holding-big-lots-and-other-big-stocks-moving-higher-on-tuesday
PDD Holdings, UP Fintech Holding, Big Lots...
08/29/2023 14:33:40

U.S. stocks traded higher, with the Dow Jones gaining around 100 points on Tuesday. Here are some big stocks recording gains in...

inhibrx-announces-200m-private-placement-financing-in-the-pipe-co-is-selling-an-aggregate-of-3621314-shares-of-its-common-stock-at-a-price-of-1935-per-share
Inhibrx Announces $200M Private Placement ...
08/29/2023 13:03:24

 Inhibrx, Inc. (NASDAQ:INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company dedicated...

jmp-securities-maintains-outperform-rating-for-inhibrx-heres-what-you-need-to-know
JMP Securities Maintains Outperform Rating...
08/23/2023 17:01:28

jmp-securities-maintains-outperform-on-inhibrx-lowers-price-target-to-27
JMP Securities Maintains Outperform on Inh...
08/23/2023 11:07:24

JMP Securities analyst Reni Benjamin maintains Inhibrx (NASDAQ:INBX) with a Outperform and lowers the price target from $35 ...

inhibrx-q2-eps-108-down-from-097-yoy-sales-3000k-down-from-71100k-yoy
Inhibrx Q2 EPS $(1.08) Down From $(0.97) Y...
08/07/2023 20:21:20

Inhibrx (NASDAQ:INBX) reported quarterly losses of $(1.08) per share. This is a 11.34 percent decrease over losses of $(0.97) p...

inhibrx-granted-fast-track-designation-for-inbrx-101-for-treatment-of-alpha-1-antitrypsin-deficiency
Inhibrx Granted Fast Track Designation For...
05/30/2023 13:03:08

Inhibrx, Inc. (NASDAQ:INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncolo...

jmp-securities-reiterates-market-outperform-on-inhibrx-maintains-35-price-target
JMP Securities Reiterates Market Outperfor...
05/10/2023 12:43:01

JMP Securities analyst Benjamin Chaiken reiterates Inhibrx (NASDAQ:INBX) with a Market Outperform and maintains $35 price ta...

inhibrx-resumes-patient-enrollment-in-inbrx-109-studies-in-cancer-patients
Inhibrx Resumes Patient Enrollment In INBR...
04/26/2023 19:18:30

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION